Print

FDA Grants Orphan Drug Designation to Biodel Inc. (BIOD)l's Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Population  
12/7/2012 9:41:11 AM

DANBURY, Conn., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that the FDA has granted orphan drug designation for Biodel's 'glucagon' for the prevention of hypoglycemia in the congenital hyperinsulinism (CHI) population.
//-->